THE IMPACT OF INTERMEDIATE TITER ANTIBODIES TO ADALIMUMAB (ATA) AND INFLIXIMAB (ATI) ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE (CD) OR ULCERATIVE COLITIS (UC)
Publication/Presentation Date
1-2021
Volume
27
Issue
1
First Page
57
Last Page
57
Published In/Presented At
Chaoyang Wang, Mazen Tolaymat, Raymond Cross, THE IMPACT OF INTERMEDIATE TITER ANTIBODIES TO ADALIMUMAB (ATA) AND INFLIXIMAB (ATI) ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE (CD) OR ULCERATIVE COLITIS (UC), Inflammatory Bowel Diseases, Volume 27, Issue Supplement_1, January 2021, Page S57, https://doi.org/10.1093/ibd/izaa347.136
Disciplines
Medicine and Health Sciences | Pediatrics
Department(s)
Department of Pediatrics
Document Type
Article
COinS